Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI) posted its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01, FiscalAI reports.

Vivani Medical Trading Down 2.2%

Shares of NASDAQ VANI traded down $0.03 during mid-day trading on Thursday, reaching $1.34. The company had a trading volume of 195,735 shares, compared to its average volume of 364,333. The stock has a market cap of $115.55 million, a PE ratio of -3.35 and a beta of 2.35. The company has a 50-day moving average price of $1.29 and a two-hundred day moving average price of $1.25. Vivani Medical has a 1-year low of $0.92 and a 1-year high of $1.92.

Insider Activity

In related news, Director Gregg Williams bought 1,587,301 shares of Vivani Medical stock in a transaction dated Monday, June 15th. The stock was acquired at an average cost of $1.26 per share, with a total value of $1,999,999.26. Following the completion of the acquisition, the director directly owned 36,119,086 shares in the company, valued at approximately $45,510,048.36. This trade represents a 4.60% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 53.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vivani Medical

Institutional investors have recently bought and sold shares of the stock. Tudor Investment Corp ET AL acquired a new stake in Vivani Medical during the 4th quarter worth about $1,127,000. Marshall Wace LLP acquired a new position in shares of Vivani Medical in the fourth quarter worth about $174,000. State Street Corp boosted its holdings in shares of Vivani Medical by 12.5% in the fourth quarter. State Street Corp now owns 144,865 shares of the company’s stock worth $178,000 after buying an additional 16,070 shares during the period. Jane Street Group LLC purchased a new position in shares of Vivani Medical in the fourth quarter worth approximately $60,000. Finally, Renaissance Technologies LLC increased its position in shares of Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after acquiring an additional 53,127 shares in the last quarter. Hedge funds and other institutional investors own 6.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Lake Street Capital assumed coverage on Vivani Medical in a research note on Tuesday, June 23rd. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings upgraded shares of Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.75.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.